Captrust Financial Advisors Has $343,000 Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Captrust Financial Advisors trimmed its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 7.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,136 shares of the company’s stock after selling 1,966 shares during the quarter. Captrust Financial Advisors’ holdings in Takeda Pharmaceutical were worth $343,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its position in Takeda Pharmaceutical by 3.2% during the third quarter. Hantz Financial Services Inc. now owns 226,685 shares of the company’s stock worth $3,223,000 after acquiring an additional 6,967 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the period. FMR LLC raised its position in shares of Takeda Pharmaceutical by 10.9% in the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after buying an additional 286,052 shares in the last quarter. Managed Asset Portfolios LLC boosted its stake in shares of Takeda Pharmaceutical by 0.3% in the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock valued at $23,001,000 after buying an additional 4,069 shares during the period. Finally, Cerity Partners LLC grew its position in Takeda Pharmaceutical by 93.1% during the third quarter. Cerity Partners LLC now owns 127,071 shares of the company’s stock worth $1,807,000 after buying an additional 61,271 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $13.42 on Friday. The firm has a market cap of $42.70 billion, a PE ratio of 23.14, a price-to-earnings-growth ratio of 0.26 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. The stock’s fifty day moving average price is $13.81 and its two-hundred day moving average price is $13.87. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.